Competition forcing marriage of iPads, ops data for execs

"We can't ignore any data telling us about the effectiveness of our business strategies," Pfizer ($PFE) VP for U.S. commercial ops David Kreutter told MIT Sloan Management Review. The stakes are too high for execs to eschew tablet PCs; "analytics has become much more operational than in the past," he said, echoing VP/GM Andy Amalfitano of Solarsoft Business Systems: "[The iPad] can be even more powerful in the hands of management, looking at every strategic advantage that could boost the bottom line. That's where manufacturing intelligence comes into play." Interview

Suggested Articles

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.